JP2020111618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020111618A5 JP2020111618A5 JP2020076575A JP2020076575A JP2020111618A5 JP 2020111618 A5 JP2020111618 A5 JP 2020111618A5 JP 2020076575 A JP2020076575 A JP 2020076575A JP 2020076575 A JP2020076575 A JP 2020076575A JP 2020111618 A5 JP2020111618 A5 JP 2020111618A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- alkyl
- composition according
- group
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 63
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 7
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 229910052805 deuterium Inorganic materials 0.000 claims 7
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- -1 -O-phenyl Chemical group 0.000 claims 5
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 235000002566 Capsicum Nutrition 0.000 claims 1
- 240000008574 Capsicum frutescens Species 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000033133 Testicular seminomatous germ cell tumor Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 206010002906 aortic stenosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000001390 capsicum minimum Substances 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000009104 chemotherapy regimen Methods 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- JIQNWFBLYKVZFY-UHFFFAOYSA-N methoxycyclohexatriene Chemical compound COC1=C[C]=CC=C1 JIQNWFBLYKVZFY-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000024662 testicular seminoma Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022015648A JP2022048352A (ja) | 2017-01-20 | 2022-02-03 | 癌関連障害の治療のためのアゾロピリミジン |
| JP2024032994A JP2024063179A (ja) | 2017-01-20 | 2024-03-05 | 癌関連障害の治療のためのアゾロピリミジン |
| JP2026018617A JP2026086620A (ja) | 2017-01-20 | 2026-02-06 | 癌関連障害の治療のためのアゾロピリミジン |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448608P | 2017-01-20 | 2017-01-20 | |
| US62/448,608 | 2017-01-20 | ||
| US201762479005P | 2017-03-30 | 2017-03-30 | |
| US62/479,005 | 2017-03-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548449A Division JP6697091B2 (ja) | 2017-01-20 | 2018-01-19 | 癌関連障害の治療のためのアゾロピリミジン |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022015648A Division JP2022048352A (ja) | 2017-01-20 | 2022-02-03 | 癌関連障害の治療のためのアゾロピリミジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020111618A JP2020111618A (ja) | 2020-07-27 |
| JP2020111618A5 true JP2020111618A5 (enExample) | 2020-09-03 |
| JP7021282B2 JP7021282B2 (ja) | 2022-02-16 |
Family
ID=62908757
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548449A Active JP6697091B2 (ja) | 2017-01-20 | 2018-01-19 | 癌関連障害の治療のためのアゾロピリミジン |
| JP2020076575A Active JP7021282B2 (ja) | 2017-01-20 | 2020-04-23 | 癌関連障害の治療のためのアゾロピリミジン |
| JP2022015648A Withdrawn JP2022048352A (ja) | 2017-01-20 | 2022-02-03 | 癌関連障害の治療のためのアゾロピリミジン |
| JP2024032994A Withdrawn JP2024063179A (ja) | 2017-01-20 | 2024-03-05 | 癌関連障害の治療のためのアゾロピリミジン |
| JP2026018617A Pending JP2026086620A (ja) | 2017-01-20 | 2026-02-06 | 癌関連障害の治療のためのアゾロピリミジン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548449A Active JP6697091B2 (ja) | 2017-01-20 | 2018-01-19 | 癌関連障害の治療のためのアゾロピリミジン |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022015648A Withdrawn JP2022048352A (ja) | 2017-01-20 | 2022-02-03 | 癌関連障害の治療のためのアゾロピリミジン |
| JP2024032994A Withdrawn JP2024063179A (ja) | 2017-01-20 | 2024-03-05 | 癌関連障害の治療のためのアゾロピリミジン |
| JP2026018617A Pending JP2026086620A (ja) | 2017-01-20 | 2026-02-06 | 癌関連障害の治療のためのアゾロピリミジン |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10399962B2 (enExample) |
| EP (2) | EP4310082A3 (enExample) |
| JP (5) | JP6697091B2 (enExample) |
| KR (1) | KR102611446B1 (enExample) |
| CN (2) | CN116768859B (enExample) |
| AU (3) | AU2018210272C1 (enExample) |
| CA (1) | CA3047600A1 (enExample) |
| CL (1) | CL2019002003A1 (enExample) |
| DK (1) | DK3570844T3 (enExample) |
| ES (1) | ES2971271T3 (enExample) |
| FI (1) | FI3570844T3 (enExample) |
| HR (1) | HRP20231157T1 (enExample) |
| HU (1) | HUE064141T2 (enExample) |
| IL (2) | IL267924B (enExample) |
| LT (1) | LT3570844T (enExample) |
| MX (2) | MX389798B (enExample) |
| MY (1) | MY202791A (enExample) |
| NZ (1) | NZ754731A (enExample) |
| PH (1) | PH12019501671A1 (enExample) |
| PL (1) | PL3570844T3 (enExample) |
| PT (1) | PT3570844T (enExample) |
| SA (1) | SA519402296B1 (enExample) |
| SG (1) | SG11201905812WA (enExample) |
| SI (1) | SI3570844T1 (enExample) |
| TW (2) | TWI812494B (enExample) |
| UA (1) | UA126863C2 (enExample) |
| UY (1) | UY37574A (enExample) |
| WO (1) | WO2018136700A1 (enExample) |
| ZA (2) | ZA201904265B (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX389798B (es) | 2017-01-20 | 2025-03-20 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer. |
| MX2019010302A (es) | 2017-03-30 | 2019-11-21 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1. |
| AU2018246355B2 (en) | 2017-03-30 | 2021-12-09 | iTeos Belgium SA | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers |
| CN110636846B (zh) * | 2017-05-17 | 2023-05-16 | 艾库斯生物科学有限公司 | 用于治疗癌症相关疾病的喹唑啉吡唑衍生物 |
| CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| JP2020527588A (ja) | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| CA3090922A1 (en) * | 2018-02-16 | 2019-08-22 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
| EP3823614A4 (en) * | 2018-07-18 | 2022-03-30 | Arcus Biosciences, Inc. | SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND |
| JP7386841B2 (ja) | 2018-07-24 | 2023-11-27 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリン化合物及びその使用 |
| AU2019312296B2 (en) * | 2018-07-27 | 2025-05-29 | Arcus Biosciences, Inc. | Pyridone A2R antagonists |
| US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| AR116315A1 (es) * | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
| BE1026612B1 (fr) | 2018-09-27 | 2020-07-02 | Iteos Therapeutics S A | Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine |
| WO2020065036A1 (en) | 2018-09-27 | 2020-04-02 | Iteos Therapeutics S.A. | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| TW202023558A (zh) | 2018-10-03 | 2020-07-01 | 美商建南德克公司 | 8-胺基異喹啉化合物及其用途 |
| AR117164A1 (es) * | 2018-11-30 | 2021-07-14 | Merck Sharp & Dohme | Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer |
| US20220016168A1 (en) * | 2018-12-11 | 2022-01-20 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
| WO2020150674A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| WO2020156505A1 (zh) * | 2019-02-02 | 2020-08-06 | 江苏恒瑞医药股份有限公司 | 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用 |
| ES3070946T3 (en) * | 2019-03-12 | 2026-06-18 | Arcus Biosciences Inc | Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation |
| CA3135487A1 (en) * | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| BR112021022538A2 (pt) * | 2019-06-06 | 2021-12-28 | Arcus Biosciences Inc | Processos para preparar compostos de aminopirimidina |
| KR102443873B1 (ko) * | 2019-09-06 | 2022-09-19 | 비욘드바이오주식회사 | 피리미딘일 바이피리딘 화합물의 제조방법 및 그를 위한 중간체 |
| CN113121502A (zh) * | 2019-12-31 | 2021-07-16 | 山东铂源生物医药有限公司 | 一种杂芳烃类化合物、中间体、组合物及应用 |
| WO2021170797A1 (en) | 2020-02-26 | 2021-09-02 | iTeos Belgium SA | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS |
| EP4122927A4 (en) * | 2020-03-16 | 2024-07-03 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | PYRIMIDINE AMINE DERIVATIVE OR SUBSTITUTED PYRIDINE AMINE DERIVATIVE, COMPOSITION AND ASSOCIATED MEDICAL USE |
| CA3173831A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
| CN113429410B (zh) * | 2020-03-23 | 2022-10-04 | 上海海雁医药科技有限公司 | 多杂环取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途 |
| BR112022019387A2 (pt) * | 2020-03-27 | 2022-11-16 | Dong A St Co Ltd | Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos |
| WO2021204626A1 (en) | 2020-04-06 | 2021-10-14 | Almirall, S.A. | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors |
| MX2022012558A (es) | 2020-04-07 | 2023-02-22 | iTeos Belgium SA | Derivados de diaminas macrocíclicas como inhibidores de ent para el tratamiento de cánceres y combinación de estos con antagonistas del receptor de adenosina. |
| TW202210514A (zh) | 2020-06-02 | 2022-03-16 | 美商阿克思生物科學有限公司 | 針對tigit的抗體 |
| CA3179320A1 (en) | 2020-06-17 | 2021-12-23 | Arcus Biosciences, Inc. | Crystalline forms of a cd73 inhibitor and uses thereof |
| CN112812095A (zh) * | 2021-01-29 | 2021-05-18 | 成都安满生物医药科技有限公司 | 一种巴洛沙韦酯中间体的合成方法 |
| WO2022166796A1 (zh) * | 2021-02-05 | 2022-08-11 | 上海齐鲁制药研究中心有限公司 | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 |
| WO2022178135A1 (en) | 2021-02-17 | 2022-08-25 | Iteos Belguim Sa | Compounds, compositions and methods of treatment thereof |
| KR20230158044A (ko) | 2021-03-18 | 2023-11-17 | 남미 테라퓨틱스, 인크. | 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법 |
| KR102646627B1 (ko) * | 2021-03-24 | 2024-03-13 | 주식회사 스탠다임 | 아데노신 a2a 수용체 및 아데노신 a2b 수용체의 이중 길항제, 및 이의 용도 |
| WO2022236256A1 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| EP4341262A1 (en) | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
| WO2023040876A1 (zh) * | 2021-09-15 | 2023-03-23 | 上海海雁医药科技有限公司 | 氮杂芳环类化合物及其药学上可接受的盐的多晶型物、药物组合物和应用 |
| CA3231951A1 (en) * | 2021-09-15 | 2023-03-23 | Shuangni ZHAO | Polymorph and application of pyrimidine derivative and pharmaceutically acceptable salt thereof |
| TW202325279A (zh) | 2021-10-29 | 2023-07-01 | 美商阿克思生物科學有限公司 | HIF-2α抑制劑及其使用方法 |
| CN116063292A (zh) * | 2021-10-29 | 2023-05-05 | 山东晶源生物医药有限公司 | 一种含氮化合物、其中间体、其组合物、其制备方法及其应用 |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| CN119156228A (zh) | 2022-05-02 | 2024-12-17 | 艾库斯生物科学有限公司 | 抗tigit抗体及其用途 |
| CN114907273B (zh) * | 2022-06-09 | 2025-02-18 | 乐威医药（江苏）股份有限公司 | 2-氨基嘧啶-6-芳基化合物的制备方法 |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202421150A (zh) | 2022-09-14 | 2024-06-01 | 美商阿克思生物科學有限公司 | 艾魯美冷之分散體 |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| CN120091809A (zh) | 2022-10-20 | 2025-06-03 | 艾库斯生物科学有限公司 | Cd73化合物的冻干制剂 |
| WO2024097736A1 (en) | 2022-11-02 | 2024-05-10 | Arcus Biosciences, Inc. | Processes for preparing azolopyrimidine compounds |
| WO2024134541A1 (en) | 2022-12-20 | 2024-06-27 | iTeos Belgium SA | Heterocyclic compounds as ent inhibitors and compounds for use in the treatment of cancers |
| EP4705292A1 (en) | 2023-05-05 | 2026-03-11 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| EP4788432A1 (en) | 2023-10-06 | 2026-08-12 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US12384773B2 (en) | 2023-11-02 | 2025-08-12 | Arcus Biosciences, Inc. | Thiazole compounds and methods of use thereof |
| TW202523332A (zh) | 2023-11-14 | 2025-06-16 | 比利時商艾托斯比利時公司 | Ｅｎｔ１抑制劑與檢查點抑制劑組合 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
| WO2025254418A1 (ko) * | 2024-06-03 | 2025-12-11 | 동아에스티 주식회사 | 아미노피리미딘 유도체의 결정다형 및 이의 제조방법 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| BR0210149A (pt) | 2001-05-09 | 2004-06-29 | Newbiotics Inc | Pródrogas ativadas por deformilase de peptìdeo |
| TWI330183B (enExample) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| CA2551944A1 (en) * | 2003-12-15 | 2005-06-30 | Almirall Prodesfarma Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| ES2431466T3 (es) * | 2006-06-30 | 2013-11-26 | Sunesis Pharmaceuticals, Inc. | Inhibidores de piridinonil pdk1 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US20110065633A1 (en) | 2008-01-30 | 2011-03-17 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009288108B2 (en) * | 2008-09-03 | 2013-10-17 | Teva Pharmaceutical Industries, Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| AR074199A1 (es) * | 2008-11-20 | 2010-12-29 | Glaxosmithkline Llc | Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer. |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| DE102011008352A1 (de) | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130269017A1 (en) * | 2012-04-04 | 2013-10-10 | Salesforce.Com, Inc. | Centralized single sign on service for websites and online services |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| CN103664908A (zh) * | 2013-12-10 | 2014-03-26 | 苏州大学 | 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物 |
| WO2017088755A1 (en) * | 2015-11-23 | 2017-06-01 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | Aminopyrimidine heterocyclic compound with adenosine receptor antagonistic activity |
| MX389798B (es) | 2017-01-20 | 2025-03-20 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer. |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| MX2019010302A (es) | 2017-03-30 | 2019-11-21 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1. |
| AR111307A1 (es) | 2017-03-30 | 2019-06-26 | Takeda Pharmaceuticals Co | Derivados de 1,2-dihidroespiro[ciclohexan-1,3-indol] o 1,2-dihidroespiro[ciclohexan-1,3-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa |
-
2018
- 2018-01-19 MX MX2019008593A patent/MX389798B/es unknown
- 2018-01-19 EP EP23194932.2A patent/EP4310082A3/en active Pending
- 2018-01-19 ES ES18741044T patent/ES2971271T3/es active Active
- 2018-01-19 WO PCT/US2018/014352 patent/WO2018136700A1/en not_active Ceased
- 2018-01-19 CA CA3047600A patent/CA3047600A1/en active Pending
- 2018-01-19 SG SG11201905812WA patent/SG11201905812WA/en unknown
- 2018-01-19 SI SI201831021T patent/SI3570844T1/sl unknown
- 2018-01-19 UA UAA201909210A patent/UA126863C2/uk unknown
- 2018-01-19 HU HUE18741044A patent/HUE064141T2/hu unknown
- 2018-01-19 NZ NZ754731A patent/NZ754731A/en unknown
- 2018-01-19 EP EP18741044.4A patent/EP3570844B1/en active Active
- 2018-01-19 HR HRP20231157TT patent/HRP20231157T1/hr unknown
- 2018-01-19 TW TW111136869A patent/TWI812494B/zh active
- 2018-01-19 FI FIEP18741044.4T patent/FI3570844T3/fi active
- 2018-01-19 US US15/875,106 patent/US10399962B2/en active Active
- 2018-01-19 AU AU2018210272A patent/AU2018210272C1/en active Active
- 2018-01-19 PT PT187410444T patent/PT3570844T/pt unknown
- 2018-01-19 KR KR1020197024140A patent/KR102611446B1/ko active Active
- 2018-01-19 CN CN202310541174.8A patent/CN116768859B/zh active Active
- 2018-01-19 CN CN201880007563.XA patent/CN110214012B/zh active Active
- 2018-01-19 MY MYPI2019003049A patent/MY202791A/en unknown
- 2018-01-19 DK DK18741044.4T patent/DK3570844T3/da active
- 2018-01-19 PL PL18741044.4T patent/PL3570844T3/pl unknown
- 2018-01-19 LT LTEPPCT/US2018/014352T patent/LT3570844T/lt unknown
- 2018-01-19 UY UY0001037574A patent/UY37574A/es active IP Right Grant
- 2018-01-19 JP JP2018548449A patent/JP6697091B2/ja active Active
- 2018-01-19 TW TW107101999A patent/TWI781136B/zh active
-
2019
- 2019-06-28 ZA ZA2019/04265A patent/ZA201904265B/en unknown
- 2019-07-02 US US16/460,263 patent/US11072597B2/en active Active
- 2019-07-08 IL IL267924A patent/IL267924B/en unknown
- 2019-07-15 SA SA519402296A patent/SA519402296B1/ar unknown
- 2019-07-17 CL CL2019002003A patent/CL2019002003A1/es unknown
- 2019-07-18 MX MX2022001360A patent/MX2022001360A/es unknown
- 2019-07-19 PH PH12019501671A patent/PH12019501671A1/en unknown
-
2020
- 2020-04-23 JP JP2020076575A patent/JP7021282B2/ja active Active
-
2021
- 2021-10-22 US US17/507,921 patent/US12195447B2/en active Active
-
2022
- 2022-01-06 IL IL289650A patent/IL289650A/en unknown
- 2022-02-03 JP JP2022015648A patent/JP2022048352A/ja not_active Withdrawn
- 2022-05-24 AU AU2022203515A patent/AU2022203515B2/en active Active
- 2022-09-08 ZA ZA2022/10004A patent/ZA202210004B/en unknown
-
2024
- 2024-03-05 JP JP2024032994A patent/JP2024063179A/ja not_active Withdrawn
- 2024-05-21 AU AU2024203366A patent/AU2024203366A1/en not_active Abandoned
-
2026
- 2026-02-06 JP JP2026018617A patent/JP2026086620A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518627A5 (enExample) | ||
| HRP20231157T1 (hr) | Azolopirimidin za liječenje poremećaja povezanih s rakom | |
| JP2019529500A5 (enExample) | ||
| Lovejoy et al. | Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo | |
| JP2022535120A5 (enExample) | ||
| Kalirajan et al. | In-silico design, ADMET screening, MM-GBSA binding free energy of some novel isoxazole substituted 9-anilinoacridines as HER2 inhibitors targeting breast cancer | |
| Makrilia et al. | Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review | |
| JP2024516997A5 (enExample) | ||
| JP2023530456A5 (enExample) | ||
| JP2024521712A5 (enExample) | ||
| Clavel et al. | Discovery of a highly tumor-selective organometallic ruthenium (II)–arene complex | |
| JP2016503414A5 (enExample) | ||
| Aruchamy et al. | Imidazole-pyridine hybrids as potent anti-cancer agents | |
| JP2018504418A5 (enExample) | ||
| JP2010538091A5 (enExample) | ||
| JP2017538677A5 (enExample) | ||
| JP2022524559A5 (enExample) | ||
| JP2022507474A5 (enExample) | ||
| JP2017525753A5 (enExample) | ||
| JP2021513965A5 (enExample) | ||
| JP2019535746A5 (enExample) | ||
| JP2017538678A5 (enExample) | ||
| RU2020102237A (ru) | Связывающие il-1-бета антитела для применения в лечении рака | |
| CA2736177A1 (en) | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases | |
| JP2024519188A5 (enExample) |